Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 12, 2002

View Archived Issues

New migraine therapy available for prescribing in the U.K.

NeuroSearch signs with development partner for NS-2330

New neuroscience company formed by Immune Network

Argatroban reduces stroke-associated mortality in HIT patients

Beneficial effects and safety demonstrated for gpIIb/IIIa antagonist in acute ischemic stroke

Field administration of MgSO4 feasible and safe in acute stroke

Phase II trial of CeaVac and TriAb initiated in metastatic colorectal cancer

Nutrition 21 identifies isomer of CLA that improves glucose metabolism without insulin

Orally administered S-23906-1 evaluated for activity in metastatic colon cancer models

Bracco licenses noninvasive Down's syndrome diagnostic test

DFB to evaluate Demegen's D2A21 antimicrobial gel with option to license

Scios reviews 2001 achievements, plans for 2002

Combination of 2-methoxyestradiol with oxidative stress associated with enhanced antitumor activity

Silico Insights and Genzyme Molecular Oncology enter oncogenic collaboration

Tracleer fails to meet primary endpoints in phase III CHF study

Pharmacia discontinues SU-5416 clinical program

Toxicology studies completed for Reolysin

Study finds fluvastatin is not associated with creatine kinase elevation

Hormone therapy more likely to improve quality of life in women with flushing

Indole derivatives as ligands of dopamine D4 and 5-HT2A receptors

Pyrazole derivatives prepared at DuPont for thromboembolic disorders

Antibacterial compounds that act as fatty acid synthase FabH inhibitors

Letrozole superior to anastrozole in reducing estrogen production in breast cancer patients

Selective ligands of nicotinic alpha4beta2 receptors claimed for treatment of memory disorders

Weight loss and exercise more effective than metformin in delaying the onset of diabetes

Pfizer claims glycine derivatives in treatment of mood disorders

Pamoic acid derivatives for Alzheimer's disease presented by Sigma-Tau

Eptifibatide protects patients one year after coronary stent implantation